@article{75d76044f473435b8cbe546370a1be7f,
title = "Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A",
author = "Smith, {Mark P.} and Jeremy Rupon and Yasser Wali and Hala Rimawi and Joan Korth-Bradley and Lynne Smith and Pablo Rendo",
note = "Funding Information: This study was sponsored by Pfizer Inc. Medical writing and editorial support were provided by Michael D. Morren, RPh, MBA, of Peloton Advantage, LLC, an OPEN Health company, and funded by Pfizer Inc. No author received an honorarium related to the development of this manuscript. Mark P. Smith, Hala Rimawi, and Yasser Wali have no conflicts to disclose. Jeremy Rupon, Joan Korth‐Bradley, and Lynne Smith are employees of Pfizer Inc and own stock in the company. Pablo Rendo was an employee of Pfizer Inc at the time of this research and may own stock in the company. Funding Information: The authors thank the participating parents and caregivers, without whom this study could not have been done. Michael Morren, RPh, MBA, of Peloton Advantage, an OPEN Health company, provided medical writing and editorial support, which were funded by Pfizer Inc. ",
year = "2020",
month = sep,
day = "1",
doi = "10.1111/hae.14047",
language = "English",
volume = "26",
pages = "e232--e235",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "5",
}